Incidence of Vasoplegic Syndrome after Cardiac Transplant in Patients Treated with Sacubitril/Valsartan

Vasoplegic syndrome (VS) is associated with high morbidity and mortality after heart transplant (HT). ACE-inhibitors have shown to increase the risk of VS after heart surgery, but little is known about the effect of Sacubitril/Valsartan (SAC/ VALS), a more potent vasodilator used in heart failure. Profound vasoplegia was reported after HT in a patient receiving SAC/VALS. We aim to assess whether SAC/VALS is associated with a higher incidence of VS in patients undergoing a HT.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: 680 Source Type: research